

Melvin L K Chua

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3184371/publications.pdf>

Version: 2024-02-01

163
papers

7,665
citations

126907
33
h-index

58581
82
g-index

174
all docs

174
docs citations

174
times ranked

12544
citing authors

#	ARTICLE	IF	CITATIONS
1	Nasopharyngeal carcinoma. Lancet, The, 2016, 387, 1012-1024.	13.7	1,045
2	SARS-CoV-2 Transmission in Patients With Cancer at a Tertiary Care Hospital in Wuhan, China. JAMA Oncology, 2020, 6, 1108.	7.1	862
3	Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma. New England Journal of Medicine, 2019, 381, 1124-1135.	27.0	573
4	A Practical Approach to the Management of Cancer Patients During the Novel Coronavirus Disease 2019 (COVID-19) Pandemic: An International Collaborative Group. Oncologist, 2020, 25, e936-e945.	3.7	520
5	Molecular landmarks of tumor hypoxia across cancer types. Nature Genetics, 2019, 51, 308-318.	21.4	480
6	Genomic hallmarks of localized, non-indolent prostate cancer. Nature, 2017, 541, 359-364.	27.8	462
7	Widespread and Functional RNA Circularization in Localized Prostate Cancer. Cell, 2019, 176, 831-843.e22.	28.9	317
8	Deep Learning for Automated Contouring of Primary Tumor Volumes by MRI for Nasopharyngeal Carcinoma. Radiology, 2019, 291, 677-686.	7.3	221
9	Identification and validation of novel microenvironment-based immune molecular subgroups of head and neck squamous cell carcinoma: implications for immunotherapy. Annals of Oncology, 2019, 30, 68-75.	1.2	196
10	Chemotherapy in Combination With Radiotherapy for Definitive-Intent Treatment of Stage II-IVA Nasopharyngeal Carcinoma: CSCO and ASCO Guideline. Journal of Clinical Oncology, 2021, 39, 840-859.	1.6	178
11	The Evolutionary Landscape of Localized Prostate Cancers Drives Clinical Aggression. Cell, 2018, 173, 1003-1013.e15.	28.9	176
12	A Prostate Cancer "Nimbus" Genomic Instability and SCHLAP1 Dysregulation Underpin Aggression of Intraductal and Cribriform Subpathologies. European Urology, 2017, 72, 665-674.	1.9	142
13	Efficacy and Safety of Locoregional Radiotherapy With Chemotherapy vs Chemotherapy Alone in De Novo Metastatic Nasopharyngeal Carcinoma. JAMA Oncology, 2020, 6, 1345.	7.1	137
14	Mitochondrial mutations drive prostate cancer aggression. Nature Communications, 2017, 8, 656.	12.8	100
15	Upconversion superballs for programmable photoactivation of therapeutics. Nature Communications, 2019, 10, 4586.	12.8	100
16	Liquid biopsy tracking during sequential chemo-radiotherapy identifies distinct prognostic phenotypes in nasopharyngeal carcinoma. Nature Communications, 2019, 10, 3941.	12.8	98
17	Neuropathological and transcriptomic characteristics of the aged brain. ELife, 2017, 6, .	6.0	97
18	Comparison of 4 modalities for distant metastasis staging in endemic nasopharyngeal carcinoma. Head and Neck, 2009, 31, 346-354.	2.0	86

#	ARTICLE	IF	CITATIONS
19	Outcomes of novel coronavirus disease 2019 (COVID-19) infection in 107 patients with cancer from Wuhan, China. <i>Cancer</i> , 2020, 126, 4023-4031.	4.1	82
20	Prognostic Model for Stratification of Radioresistant Nasopharynx Carcinoma to Curative Salvage Radiotherapy. <i>Journal of Clinical Oncology</i> , 2018, 36, 891-899.	1.6	81
21	Implementation and Outcomes of Virtual Care Across a Tertiary Cancer Center During COVID-19. <i>JAMA Oncology</i> , 2021, 7, 597.	7.1	71
22	Stereotactic Ablative Radiotherapy for the Management of Spinal Metastases. <i>JAMA Oncology</i> , 2020, 6, 567.	7.1	64
23	Pan-cancer analysis connects tumor matrisome to immune response. <i>Npj Precision Oncology</i> , 2019, 3, 15.	5.4	58
24	Residual DNA and chromosomal damage in ex vivo irradiated blood lymphocytes correlated with late normal tissue response to breast radiotherapy. <i>Radiotherapy and Oncology</i> , 2011, 99, 362-366.	0.6	54
25	Neutrophil-to-lymphocyte ratio as a prognostic marker in locally advanced nasopharyngeal carcinoma: A pooled analysis of two randomised controlled trials. <i>European Journal of Cancer</i> , 2016, 67, 119-129.	2.8	49
26	Genome-wide germline correlates of the epigenetic landscape of prostate cancer. <i>Nature Medicine</i> , 2019, 25, 1615-1626.	30.7	45
27	Characteristics of Radiotherapy Trials Compared With Other Oncological Clinical Trials in the Past 10 Years. <i>JAMA Oncology</i> , 2018, 4, 1073.	7.1	44
28	Immune checkpoint inhibitors in advanced nasopharyngeal carcinoma: Beyond an era of chemoradiation?. <i>International Journal of Cancer</i> , 2020, 146, 2305-2314.	5.1	44
29	International Recommendations on Reirradiation by Intensity Modulated Radiation Therapy for Locally Recurrent Nasopharyngeal Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 682-695.	0.8	42
30	Comparison of radiomics tools for image analyses and clinical prediction in nasopharyngeal carcinoma. <i>British Journal of Radiology</i> , 2019, 92, 20190271.	2.2	38
31	Rare Germline Variants in ATM Predispose to Prostate Cancer: A PRACTICAL Consortium Study. <i>European Urology Oncology</i> , 2021, 4, 570-579.	5.4	38
32	Translating a Prognostic DNA Genomic Classifier into the Clinic: Retrospective Validation in 563 Localized Prostate Tumors. <i>European Urology</i> , 2017, 72, 22-31.	1.9	37
33	Anti-epidermal growth factor receptor (EGFR) monoclonal antibody combined with cisplatin and 5-fluorouracil in patients with metastatic nasopharyngeal carcinoma after radical radiotherapy: a multicentre, open-label, phase II clinical trial. <i>Annals of Oncology</i> , 2019, 30, 637-643.	1.2	37
34	Genomic Classifier for Guiding Treatment of Intermediate-Risk Prostate Cancers to Dose-Escalated Image Guided Radiation Therapy Without Hormone Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 103, 84-91.	0.8	36
35	Dysregulation of the MiR-449b target TGFBI alters the TGF β ² pathway to induce cisplatin resistance in nasopharyngeal carcinoma. <i>Oncogenesis</i> , 2018, 7, 40.	4.9	34
36	Somatostatin receptor 2 expression in nasopharyngeal cancer is induced by Epstein Barr virus infection: impact on prognosis, imaging and therapy. <i>Nature Communications</i> , 2021, 12, 117.	12.8	34

#	ARTICLE	IF	CITATIONS
37	A Deep Learning-Based Automated CT Segmentation of Prostate Cancer Anatomy for Radiation Therapy Planning-A Retrospective Multicenter Study. <i>Diagnostics</i> , 2020, 10, 959.	2.6	33
38	A Radiomics Model for Predicting the Response to Bevacizumab in Brain Necrosis after Radiotherapy. <i>Clinical Cancer Research</i> , 2020, 26, 5438-5447.	7.0	32
39	Combinatorial strategies of radiotherapy and immunotherapy in nasopharyngeal carcinoma. <i>Chinese Clinical Oncology</i> , 2018, 7, 15-15.	1.2	31
40	Impact of cancer diagnoses on the outcomes of patients with COVID-19: a systematic review and meta-analysis. <i>BMJ Open</i> , 2022, 12, e044661.	1.9	30
41	Clinical outcomes of coronavirus disease 2019 (COVID-19) in cancer patients with prior exposure to immune checkpoint inhibitors. <i>Cancer Communications</i> , 2020, 40, 374-379.	9.2	29
42	Recent advances in radiation therapy and photodynamic therapy. <i>Applied Physics Reviews</i> , 2021, 8, .	11.3	29
43	DNA double-strand break repair and induction of apoptosis in ex vivo irradiated blood lymphocytes in relation to late normal tissue reactions following breast radiotherapy. <i>Radiation and Environmental Biophysics</i> , 2014, 53, 355-364.	1.4	28
44	Carcinogenesis of nasopharyngeal carcinoma: an alternate hypothetical mechanism. <i>Chinese Journal of Cancer</i> , 2016, 35, 9.	4.9	28
45	A Prospective 10-Year Observational Study of Reduction of Radiation Therapy Clinical Target Volume and Dose in Early-Stage Nasopharyngeal Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 107, 672-682.	0.8	22
46	Inter-individual and inter-cell type variation in residual DNA damage after in vivo irradiation of human skin. <i>Radiotherapy and Oncology</i> , 2011, 99, 225-230.	0.6	21
47	De-Escalation Strategies in HPV-Associated Oropharynx Cancer“Are we Putting the Cart Before the Horse?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 705-709.	0.8	21
48	Outcomes in Radiotherapy-Treated Patients With Cancer During the COVID-19 Outbreak in Wuhan, China. <i>JAMA Oncology</i> , 2020, 6, 1457.	7.1	21
49	Intensity-modulated radiotherapy for paranasal sinuses and base of skull tumors. <i>Oral Oncology</i> , 2018, 86, 61-68.	1.5	20
50	Gemcitabine: a game changer in nasopharyngeal carcinoma. <i>Lancet, The</i> , 2016, 388, 1853-1854.	13.7	19
51	Improved outcomes with dose escalation in localized prostate cancer treated with precision image-guided radiotherapy. <i>Radiotherapy and Oncology</i> , 2017, 123, 459-465.	0.6	18
52	Advances in nasopharyngeal carcinoma“West meets East“. <i>British Journal of Radiology</i> , 2019, 92, 20199004.	2.2	17
53	Multidisciplinary team meetings “ challenges of implementation science. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 205-206.	27.6	17
54	Targeting DNA repair for precision radiotherapy: Balancing the therapeutic ratio. <i>Current Problems in Cancer</i> , 2017, 41, 265-272.	2.0	16

#	ARTICLE	IF	CITATIONS
55	Adjuvant capecitabine in locoregionally advanced nasopharyngeal carcinoma: A multicenter randomized controlled phase III trial.. Journal of Clinical Oncology, 2021, 39, 6005-6005.	1.6	16
56	Testosterone in Androgen Receptor Signaling and DNA Repair: Enemy or Frenemy?. Clinical Cancer Research, 2016, 22, 3124-3126.	7.0	15
57	Vandetanib sensitizes head and neck squamous cell carcinoma to photodynamic therapy through modulation of EGFR-dependent DNA repair and the tumour microenvironment. Photodiagnosis and Photodynamic Therapy, 2019, 27, 367-374.	2.6	15
58	Retreatment in locally recurrent nasopharyngeal carcinoma: Current status and perspectives. Cancer Communications, 2021, 41, 361-370.	9.2	15
59	Dose-escalated intensity-modulated radiotherapy and irradiation of subventricular zones in relation to tumor control outcomes of patients with glioblastoma multiforme. OncoTargets and Therapy, 2016, 9, 1115.	2.0	14
60	Intraductal Carcinoma of the Prostate: Anonymous to Ominous. European Urology, 2017, 72, 496-498.	1.9	14
61	The evolution of Epstein-Barr virus detection in nasopharyngeal carcinoma. Cancer Biology and Medicine, 2018, 15, 1.	3.0	14
62	Matrix metalloproteinaseâ€1 facilitates ^{MSC} migration via cleavage of ^{IGF}/^{IGFBP}2 complex. FEBS Open Bio, 2018, 8, 15-26.	2.3	13
63	Determining the Impact of Spatial Heterogeneity on Genomic Prognostic Biomarkers for Localized Prostate Cancer. European Urology Oncology, 2020, , .	5.4	13
64	A nomogram to predict symptomatic epilepsy in patients with radiation-induced brain necrosis. Neurology, 2020, 95, e1392-e1403.	1.1	13
65	Stereotactic body radiotherapy for early stage lung cancerâ€”historical developments and future strategies. Chinese Clinical Oncology, 2017, 6, S20-S20.	1.2	13
66	⁶⁸Gallium-labelled PSMA-PET/CT as a diagnostic and clinical decision-making tool in Asian prostate cancer patients following prostatectomy. Cancer Biology and Medicine, 2019, 16, 157.	3.0	12
67	Germline Polymorphisms and Length of Survival of Nasopharyngeal Carcinoma: An Exomeâ€Wide Association Study in Multiple Cohorts. Advanced Science, 2020, 7, 1903727.	11.2	12
68	A genome-wide association study of radiotherapy induced toxicity in head and neck cancer patients identifies a susceptibility locus associated with mucositis. British Journal of Cancer, 2022, 126, 1082-1090.	6.4	12
69	Correlation between DNA damage responses of skin to a test dose of radiation and late adverse effects of earlier breast radiotherapy. Radiotherapy and Oncology, 2016, 119, 244-249.	0.6	11
70	Efficacy and safety of apatinib in recurrent/metastatic nasopharyngeal carcinoma: A pilot study. Oral Oncology, 2021, 115, 105222.	1.5	11
71	Improving the therapeutic ratio of radiotherapy against radioresistant cancers: Leveraging on novel artificial intelligence-based approaches for drug combination discovery. Cancer Letters, 2021, 511, 56-67.	7.2	11
72	Financial toxicities of cancer in lowâ€and middleâ€income countries: Perspectives from Southeast Asia. Cancer, 2022, 128, 3013-3015.	4.1	11

#	ARTICLE	IF	CITATIONS
73	Weak expression of cyclooxygenase-2 is associated with poorer outcome in endemic nasopharyngeal carcinoma: analysis of data from randomized trial between radiation alone versus concurrent chemo-radiation (SQNP-01). Radiation Oncology, 2009, 4, 23.	2.7	10
74	Adaptive radiotherapy for head and neck cancers: Fact or fallacy to improve therapeutic ratio?. Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique, 2018, 22, 287-295.	1.4	9
75	Lactate dehydrogenase kinetics predict chemotherapy response in recurrent metastatic nasopharyngeal carcinoma. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592097005.	3.2	9
76	Randomised prospective phase II trial in multiple brain metastases comparing outcomes between hippocampal avoidance whole brain radiotherapy with or without simultaneous integrated boost: HA-SIB-WBRT study protocol. BMC Cancer, 2020, 20, 1045.	2.6	9
77	Surgery as an alternative to radiotherapy in early-stage nasopharyngeal carcinoma: innovation at the expense of uncertainty. Cancer Communications, 2020, 40, 119-121.	9.2	9
78	SSTR2 in Nasopharyngeal Carcinoma: Relationship with Latent EBV Infection and Potential as a Therapeutic Target. Cancers, 2021, 13, 4944.	3.7	9
79	Development of a risk classification system combining TN-categories and circulating EBV DNA for non-metastatic NPC in 10,149 endemic cases. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110524.	3.2	9
80	Correlation between the radiation responses of fibroblasts cultured from individual patients and the risk of late reaction after breast radiotherapy. Cancer Letters, 2016, 374, 324-330.	7.2	8
81	Identifying optimal clinical trial candidates for locoregionally advanced nasopharyngeal carcinoma: Analysis of 9468 real-world cases and validation by two phase 3 multicentre, randomised controlled trial. Radiotherapy and Oncology, 2022, 167, 179-186.	0.6	8
82	Amplified parallel antigen rapid test for point-of-care salivary detection of SARS-CoV-2 with improved sensitivity. Mikrochimica Acta, 2022, 189, 14.	5.0	8
83	Real-world outcome with abiraterone acetate plus prednisone in Asian men with metastatic castrate-resistant prostate cancer: The Singapore experience. Asia-Pacific Journal of Clinical Oncology, 2020, 16, 75-79.	1.1	7
84	Evolution of Cancer Care in Response to the COVID-19 Pandemic. Oncologist, 2020, 25, e1426-e1427.	3.7	7
85	Recommendations for postoperative radiotherapy in head & neck squamous cell carcinoma in the presence of flaps: A GORTEC internationally-reviewed HNCIG-endorsed consensus. Radiotherapy and Oncology, 2021, 160, 140-147.	0.6	7
86	Follow-Up and Management of Patients With Head and Neck Cancer During the 2019 Novel Coronavirus (SARS-CoV-2) Disease Pandemic. Advances in Radiation Oncology, 2020, 5, 631-636.	1.2	6
87	Duration-dependent margins for prostate radiotherapy—a practical motion mitigation strategy. Strahlentherapie Und Onkologie, 2020, 196, 657-663.	2.0	6
88	NEAR trial: A single-arm phase II trial of neoadjuvant apalutamide monotherapy and radical prostatectomy in intermediate- and high-risk prostate cancer. Prostate Cancer and Prostatic Diseases, 2022, .	3.9	6
89	JUPITER-02 trial: advancing survival for recurrent metastatic nasopharyngeal carcinoma and next steps. Cancer Communications, 2022, 42, 56-59.	9.2	6
90	Adjuvant treatment following radical cystectomy for muscle-invasive urothelial carcinoma and variant histologies: Is there a role for radiotherapy?. ESMO Open, 2017, 2, e000123.	4.5	5

#	ARTICLE	IF	CITATIONS
91	Optimal sequencing of chemotherapy with chemoradiotherapy based on TNM stage classification and EBV DNA in locoregionally advanced nasopharyngeal carcinoma. <i>Cancer Communications</i> , 2019, 39, 1-3.	9.2	5
92	Electronic tumor board presentations as the basis for the development of a head and neck cancer database. <i>Laryngoscope Investigative Otolaryngology</i> , 2020, 5, 46-54.	1.5	5
93	Bevacizumab Combined with Corticosteroids Does Not Improve the Clinical Outcome of Nasopharyngeal Carcinoma Patients With Radiation-Induced Brain Necrosis. <i>Frontiers in Oncology</i> , 2021, 11, 746941.	2.8	5
94	Analysis of T cell receptor clonotypes in tumor microenvironment identifies shared cancer-type-specific signatures. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 989-998.	4.2	5
95	Managing advanced prostate cancer in the Asia Pacific region: â€œRealâ€worldâ€application of Advanced Prostate Cancer Consensus Conference 2019 statements. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2022, 18, 686-695.	1.1	5
96	Efficacy and Safety of Apatinib for Radiation-induced Brain Injury Among Patients With Head and Neck Cancer: An Open-Label, Single-Arm, Phase 2 Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 113, 796-804.	0.8	5
97	An evaluation of concordance between head and neck advanced practice radiation therapist and radiation oncologists in toxicity assessment for nasopharyngeal carcinoma patients. <i>Technical Innovations and Patient Support in Radiation Oncology</i> , 2021, 19, 52-56.	1.9	4
98	Nasopharyngeal carcinomaâ€past lessons and a glimpse into the future. <i>Chinese Clinical Oncology</i> , 2016, 5, 14-14.	1.2	4
99	Exploiting molecular genomics in precision radiation oncology: a marriage of biological and physical precision. <i>Chinese Clinical Oncology</i> , 2017, 6, S19-S19.	1.2	4
100	Coming of age of bevacizumab in the management of radiation-induced cerebral necrosis. <i>Annals of Translational Medicine</i> , 2019, 7, 155-155.	1.7	4
101	Adolescents and young adults with cancer: Considerations from the Southeast Asian perspective. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29593.	1.5	4
102	Efficacy, toxicity, and qualityâ€ofâ€life outcomes of ultrahypofractionated radiotherapy in patients with localized prostate cancer: A singleâ€arm phase 2 trial from Asia. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2022, 18, .	1.1	4
103	Circulating Tumor DNA to Personalize Treatment in Nasopharynx Cancer â€Time to Look â€Aheadâ€?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 362-364.	0.8	3
104	The metabolic footprint during adipocyte commitment highlights ceramide modulation as an adequate approach for obesity treatment. <i>EBioMedicine</i> , 2020, 51, 102605.	6.1	3
105	High-Dimensional Characterization of the Systemic Immune Landscape Informs on Synergism Between Radiation Therapy and Immune Checkpoint Blockade. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 70-80.	0.8	3
106	Risk of COVID-19 in Patients With Cancerâ€Reply. <i>JAMA Oncology</i> , 2020, 6, 1472.	7.1	3
107	Four Influential Clinical Trials in Human Papilloma Virus-Associated Oropharynx Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 106, 893-899.	0.8	3
108	Reply to Colorectal cancer and COVIDâ€19: Do we need to raise awareness and vigilance?. <i>Cancer</i> , 2021, 127, 980-981.	4.1	3

#	ARTICLE	IF	CITATIONS
109	A comparative analysis between low-dose-rate brachytherapy and external beam radiation therapy for low- and intermediate-risk prostate cancer in Asian men. <i>Acta Oncol</i> , 2021, 60, 1291-1295.	1.8	3
110	Why we should give spatially fractionated radiation therapy (GRID) a second look—especially in nasopharyngeal carcinoma. <i>Annals of Nasopharynx Cancer</i> , 2018, 1, 1-1.	0.3	2
111	Intra-patient and inter-patient comparisons of DNA damage response biomarkers in Nasopharynx Cancer (NPC): analysis of NCC0901 randomised controlled trial of induction chemotherapy in locally advanced NPC. <i>BMC Cancer</i> , 2018, 18, 1095.	2.6	2
112	Discovering biomarkers of radioresistance in a radiosensitive cancer: a clinical paradox in nasopharyngeal carcinoma. <i>Annals of Translational Medicine</i> , 2020, 8, 1284-1284.	1.7	2
113	Subpathologies and genomic classifier for treatment individualization of post-prostatectomy radiotherapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 5.e1-5.e13.	1.6	2
114	Repurposing Proton Beam Therapy through Novel Insights into Tumour Radioresistance. <i>Clinical Oncology</i> , 2021, 33, e469-e481.	1.4	2
115	Nasopharyngeal carcinoma—some closing remarks. <i>Chinese Clinical Oncology</i> , 2016, 5, 29-29.	1.2	2
116	Maintenance Capecitabine in Recurrent or Metastatic Nasopharyngeal Carcinoma—Magic Bullet or Pandora's Box?. <i>JAMA Oncology</i> , 2022, , .	7.1	2
117	Curative Radiation Therapy at Time of Progression Under Active Surveillance Compared With Up-front Radical Radiation Therapy for Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 702-709.	0.8	1
118	Immunotherapy in Head and Neck Cancer—Ready for Prime Time or More Research Needed?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 647-650.	0.8	1
119	Lymphocyte apoptosis as a predictive biomarker for radiotherapy de-intensification in EBV-associated nasopharynx cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, e17545-e17545.	1.6	1
120	The impact of intratumoral heterogeneity on prognostic biomarkers in localized prostate cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, 46-46.	1.6	1
121	Immune dysregulation underpins radioresistance in nasopharyngeal carcinoma (NPC).. <i>Journal of Global Oncology</i> , 2019, 5, 52-52.	0.5	1
122	The promise of stereotactic body radiotherapy—next phase of integration into oncological practice. <i>Chinese Clinical Oncology</i> , 2017, 6, S8-S8.	1.2	1
123	A multicenter prospective observational study of nutritional status on survival in locally advanced nasopharynx cancer treated by induction chemotherapy and chemoradiotherapy.. <i>Journal of Clinical Oncology</i> , 2019, 37, 6036-6036.	1.6	1
124	Identifying Patients With Low-Risk Locoregionally Advanced Nasopharyngeal Carcinoma by Plasma Epstein-Barr Virus DNA for Chemotherapy Deintensification: Quo Vadis?. <i>Journal of Clinical Oncology</i> , 2022, 40, 1135-1138.	1.6	1
125	MP14-04 OUTCOMES OF RADIATION FOLLOWING EXPECTANT MANAGEMENT FOR LOW RISK, LOCALIZED PROSTATE CANCER. <i>Journal of Urology</i> , 2016, 195, .	0.4	0
126	Dosimetric uncertainties impact on cell survival curve with low energy proton. <i>Physica Medica</i> , 2020, 76, 277-284.	0.7	0

#	ARTICLE	IF	CITATIONS
127	In Reply. Oncologist, 2020, 25, e1252-e1253.	3.7	0
128	Investigation of a 22-gene genomic classifier (GC) for risk stratification and molecular subtyping in an Asian prostate cancer (PCa) cohort.. Journal of Clinical Oncology, 2021, 39, 249-249.	1.6	0
129	Re-irradiation versus surgery for locally recurrent nasopharyngeal carcinoma. Lancet Oncology, The, 2021, 22, e217.	10.7	0
130	PSY3-4 AI for practice. Annals of Oncology, 2021, 32, S241.	1.2	0
131	Something for Everyone From Low-Risk to High-Risk: 5 Recent Studies to Improve Treatment and Surveillance for All Patients With Squamous Cell Carcinoma of the Head and Neck. International Journal of Radiation Oncology Biology Physics, 2021, 111, 1-8.	0.8	0
132	Intraductal carcinoma and cribriform architecture as novel prognostic factors in patients with prostate cancer treated with dose-escalated radiotherapy.. Journal of Clinical Oncology, 2016, 34, 101-101.	1.6	0
133	Copy number alterations of P53, RB1, and MDM2 as prognostic markers in intermediate-risk prostate cancer.. Journal of Clinical Oncology, 2016, 34, 117-117.	1.6	0
134	Copy number alterations of DNA mismatch repair (MMR) genes as novel prognostic markers in localised prostate cancer (CaP).. Journal of Clinical Oncology, 2016, 34, 96-96.	1.6	0
135	Prognostic value of copy-number alterations of the Cohesin complex in intermediate-risk prostate cancer recurrence.. Journal of Clinical Oncology, 2016, 34, 49-49.	1.6	0
136	Combinatorial genomic and pathological indices for integrated stratification of unfavorable intermediate-risk prostate cancer.. Journal of Clinical Oncology, 2016, 34, 5051-5051.	1.6	0
137	Abstract 4339: Prognostic significance of copy number alteration burden in unfavorable intermediate-risk prostate cancers harboring intraductal carcinoma and cribriform architecture. , 2016, , .		0
138	Treatment of Viral-Associated HNC (OPC and NPC). , 2017, , 177-188.		0
139	Oncologic outcomes of radiation therapy following active surveillance for low- and intermediate-risk localized prostate cancer.. Journal of Clinical Oncology, 2017, 35, 42-42.	1.6	0
140	Genomic architecture of radioresistant prostate cancer.. Journal of Clinical Oncology, 2017, 35, 26-26.	1.6	0
141	Abstract B39: Tumor hypoxia induces DNA repair vulnerabilities through contextual loss-of-heterozygosity, 2017, , .		0
142	Abstract A28: Mutational landscape of TP53 in localized prostate cancer. , 2017, , .		0
143	Abstract 2486: Tumor hypoxia induces DNA repair vulnerabilities through contextual loss of heterozygosity. , 2017, , .		0
144	Abstract 5860: Genomic architecture of prostate cancer at recurrence following radiotherapy. , 2017, , .		0

#	ARTICLE	IF	CITATIONS
145	Abstract 1794: Lymphocyte apoptosis as a predictive biomarker for radiotherapy de-intensification in EBV-associated nasopharynx cancer. , 2017, , .		0
146	A biopsy-based genomic classifier to predict biochemical failure after definitive radiation without hormone therapy in a prospective cohort of intermediate risk prostate cancer.. Journal of Clinical Oncology, 2018, 36, 68-68.	1.6	0
147	68-Ga prostate-specific membrane antigen-PET as a diagnostic and clinical decision making tool in biochemical recurrences post-radical prostatectomy.. Journal of Clinical Oncology, 2018, 36, 377-377.	1.6	0
148	â€œCor Occidereâ€ a novel strategy of targeting the tumor core by radiosurgery in a radio- and chemo-resistant intracranial hemangiopericytoma. Chinese Clinical Oncology, 2018, 7, 10-10.	1.2	0
149	Retroperitoneal Knee Pain: An Unusual Case Report and Review of an Ancient Schwannoma. Cureus, 2018, 10, e2216.	0.5	0
150	A radiomics signature for treatment stratification in advanced and recurrent nasopharynx cancer.. Journal of Clinical Oncology, 2018, 36, e18060-e18060.	1.6	0
151	Dependency of radiotherapy and combinatorial radio-immunotherapy responses on the systemic t cell immune response.. Journal of Clinical Oncology, 2018, 36, 12056-12056.	1.6	0
152	Editorial Comment. Journal of Urology, 2019, 201, 291-291.	0.4	0
153	The role of high-dimensional profiling of the systemic immune response on optimal sequencing of radiotherapy (RT) and immune checkpoint blockade (ICB).. Journal of Clinical Oncology, 2019, 37, 13-13.	1.6	0
154	The molecular hallmarks and clinical consequences of tumor hypoxia in prostate cancer.. Journal of Clinical Oncology, 2019, 37, 81-81.	1.6	0
155	Clinical and genetic determinants of toxicity and quality-of-life (QOL) outcomes for SBRT in Asian prostate cancer.. Journal of Clinical Oncology, 2019, 37, 95-95.	1.6	0
156	Longitudinal circulating Epsteinâ€Barr virus DNA response to induction chemotherapy and chemo-radiotherapy to identify biological phenotypes in EBV-associated nasopharynx of head and neck cancer.. Journal of Clinical Oncology, 2019, 37, 6021-6021.	1.6	0
157	Development of a clinicomolecular risk stratification system for nonmetastatic nasopharyngeal carcinoma using Epsteinâ€Barr virus DNA and TNM stage: A â€œBig dataâ€ analysis of 9,160 endemic cases.. Journal of Clinical Oncology, 2019, 37, 6043-6043.	1.6	0
158	Abstract 527: High-dimensional profiling of the systemic immune response informs on optimal sequencing of radiotherapy (RT) and immune checkpoint blockade (ICB). , 2019, , .		0
159	The hunt for the perfect biomarker in nasopharyngeal carcinomaâ€”the RRAS â€œraceâ€ beyond Epstein-Barr virus?. Translational Cancer Research, 2019, 8, 1659-1662.	1.0	0
160	Preliminary outcomes of a prospective observational study of combinatorial abiraterone acetate/enzalutamide (AA/Enz) and radical radiotherapy (RT) in nonmetastatic node-positive (N+M0) prostate cancer (PCa).. Journal of Clinical Oncology, 2020, 38, 227-227.	1.6	0
161	The Uro-Oncology Multi-disciplinary team (MDT) Clinic â€ Clinical and Patient-Reported Outcomes From Implementing a New Model of Care. Proceedings of Singapore Healthcare, 0, , 201010582110552.	0.6	0
162	In Reply to Abbasi et al.. International Journal of Radiation Oncology Biology Physics, 2022, 112, 262-263.	0.8	0

#	ARTICLE	IF	CITATIONS
163	A Bit More Here and a Little Less There: The Trials (and Tribulations) of Adjuvant and Neoadjuvant Head and Neck Studies in 2021. International Journal of Radiation Oncology Biology Physics, 2022, 113, 243-251.	0.8	0